LegoChem Biosciences Inc Market Cap ($1.52 Billion)
Market Cap & Net Worth: LegoChem Biosciences Inc (141080)
LegoChem Biosciences Inc market cap. LegoChem Biosciences Inc (KQ:141080) has a market capitalization of $1.52 Billion (₩2.25 Trillion) as of November 4, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #6923 globally and #164 in its home market, demonstrating a -9.53% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying LegoChem Biosciences Inc's stock price ₩61700.00 by its total outstanding shares 36439548 (36.44 Million). Also see LegoChem Biosciences Inc cash conversion from operations for how efficiently the company converts equity into cash flow.
LegoChem Biosciences Inc Market Cap History (2015–2026)
LegoChem Biosciences Inc market cap history from 2015 to 2026. Data shows growth from $308.06 Million to $1.52 Billion (16.43% CAGR). Check today's stock price for LegoChem Biosciences Inc for real-time trading data and today's change.
Index Memberships
LegoChem Biosciences Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Kosdaq Composite Index
KOSDAQ
|
$211.91 Billion | 0.72% | #21 of 1384 |
|
Kosdaq Composite Index
KQ11
|
$211.91 Billion | 0.72% | #21 of 1384 |
Weight: LegoChem Biosciences Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
LegoChem Biosciences Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how LegoChem Biosciences Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore 141080 net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.03x
LegoChem Biosciences Inc's market cap is 0.03 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $437.71 Million | $16.66 Billion | -$14.72 Billion | 0.03x | N/A |
| 2017 | $496.98 Million | $22.06 Billion | -$12.93 Billion | 0.02x | N/A |
| 2018 | $700.09 Million | $25.24 Billion | -$25.77 Billion | 0.03x | N/A |
| 2019 | $651.94 Million | $57.50 Billion | $13.59 Billion | 0.01x | 0.05x |
| 2020 | $1.73 Billion | $49.39 Billion | -$6.99 Billion | 0.04x | N/A |
| 2021 | $1.38 Billion | $32.16 Billion | -$23.39 Billion | 0.04x | N/A |
| 2022 | $1.06 Billion | $33.41 Billion | -$45.09 Billion | 0.03x | N/A |
| 2023 | $1.61 Billion | $34.15 Billion | -$73.70 Billion | 0.05x | N/A |
| 2024 | $2.69 Billion | $125.90 Billion | $7.80 Billion | 0.02x | 0.35x |
| 2025 | $4.29 Billion | $141.55 Billion | -$74.28 Billion | 0.03x | N/A |
Competitor Companies of 141080 by Market Capitalization
Companies near LegoChem Biosciences Inc in the global market cap rankings as of November 4, 2026. Also see 141080 total assets for a full breakdown of the balance sheet.
Key companies related to LegoChem Biosciences Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #372 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #411 globally with a market cap of $69.05 Billion USD ( AU$97.59 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #497 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $553.15 |
| #372 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $961.26 |
| #411 | CSL Ltd | AU:CSL | $69.05 Billion | AU$201.16 |
| #497 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $220.83 |
Market Capitalization of LegoChem Biosciences Inc (2015–2026)
Market capitalization of LegoChem Biosciences Inc from 2015 to today. Between 2015 and today, LegoChem Biosciences Inc's market cap moved from $308.06 Million to $ 1.52 Billion, with a yearly change of 16.43%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩1.52 Billion | -64.48% |
| 2025 | ₩4.29 Billion | +59.36% |
| 2024 | ₩2.69 Billion | +67.69% |
| 2023 | ₩1.61 Billion | +51.69% |
| 2022 | ₩1.06 Billion | -23.21% |
| 2021 | ₩1.38 Billion | -20.40% |
| 2020 | ₩1.73 Billion | +165.53% |
| 2019 | ₩651.94 Million | -6.88% |
| 2018 | ₩700.09 Million | +40.87% |
| 2017 | ₩496.98 Million | +13.54% |
| 2016 | ₩437.71 Million | +42.08% |
| 2015 | ₩308.06 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 3rd, 2026 the market cap of LegoChem Biosciences Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.52 Billion USD |
| MoneyControl | $1.52 Billion USD |
| MarketWatch | $1.52 Billion USD |
| marketcap.company | $1.52 Billion USD |
| Reuters | $1.52 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About LegoChem Biosciences Inc
LigaChem Biosciences Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of medicines for unmet medical needs. The company researches and develops products for various therapeutic areas, including antibiotics, anti-fibrotics, immuno-oncology, oncology; and antibody-drug conjugate (ADC) platform technology and small molecule drugs. It also sells medical devic… Read more